Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 1999

View Archived Issues

Palatin awarded 4th and 5th SBIR grants for MIDAS technology

Schering-Plough initiates manufacture of Vasomax

Positive ribavirin study results reported in the Journal of Hepatology

Spotlight update: fibrinogen (gpIIb/IIIa) receptor antagonists

Atrix expands drug delivery patent portfolio

Antiplatelet agents under research at Monsanto

Potent nAChR receptor agonists with heterocyclic structure patented by Astra

Magainin awarded SBIR grant for squalamine

New joint venture will invest in Australian life sciences and medical technologies

Novo Nordisk discloses new potassium channel modulators and use in endocrine and other disorders

French investigators describe potent and selective dopamine D3 agonists

Lilly introduces new insulin dosing forms with improved convenience

Merck & Co.'s new thrombin inhibitors

FDA advisory committee to review another NDA for Temodal in March

Placebo-controlled study supports the efficacy of Alrex in seasonal allergic conjunctivitis

Clinical trial shows HP-3 effective in COPD

Immunomedics' new immunotoxin against CEA is first in its class

Valspodar plus chemotherapy in the treatment of relapsed or refractory AML

Medarex reacquires worldwide rights to MDX-210

DSRB recommends continuation of Bextra study

Botulinum toxin compared to pneumatic dilatation in patients with achalasia

Licensing opportunity from BTG: antiasthmatic compound with a novel mechanism of action

Photofrin approved in Finland

Small pilot study demonstrates efficacy and safety of IL-2 with concomitant antiretroviral therapy

European CPMP recommends approval of Integrilin for acute coronary syndrome

European authorities okay merger of Astra and Zeneca

PPL's initial results of AAT trial in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...